ArticleJournal of gastroenterology2026
Impact of 5-aminosalicylic acid intolerance on progression to difficult-to-treat ulcerative colitis: a retrospective cohort study.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIntolerance to 5-aminosalicylic acid (5-ASA) is linked to poorer outcomes in ulcerative colitis (UC), but its impact on progression to difficult-to-treat (D2T) disease and the contribution of specific intolerance phenotypes remain uncertain. We evaluated the long-term prognostic impact of 5-ASA intolerance phenotypes and post-intolerance treatment status.
methodsThis retrospective cohort study included 919 patients with UC. Cumulative incidence functions were compared using Gray's test, treating death and colectomy as competing events when assessing progression to D2T. Multivariable models were adjusted for baseline covariates and immunomodulator use. Landmark analyses and sensitivity analyses using secondary failure of ≥ 2 mechanisms of action after advanced therapy initiation were performed.
resultsAmong 919 patients, 145 (15.8%) were classified as 5-ASA intolerant, including 83 with acute intolerance syndrome (AIS) and 62 with non-AIS phenotypes. Overall intolerance was independently associated with an increased risk of D2T progression (subdistribution hazard ratio [sHR] 2.07, 95% confidence interval [CI] 1.14-3.75), but not with colectomy. The excess risk was largely driven by AIS (sHR: 3.25, 95% CI: 1.64-6.45). Landmark analyses showed that 5-ASA users at 90 or 365 days exhibited a lower cumulative incidence of D2T progression than non-users. Furthermore, following advanced therapy initiation, overall 5-ASA intolerance was not associated with secondary failure of ≥ 2 mechanisms of action, whereas AIS remained independently associated with this outcome.
conclusionsProgression to D2T UC among patients with 5-ASA intolerance is largely attributable to AIS. Careful characterization of 5-ASA phenotype may improve risk stratification and inform individualized therapeutic strategies in UC management.
Indexed as
Identifiers
42521877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.